Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 6, 1999, Pages 602-608

  Laine, Kari ^a   Palovaara, Sanna ^b   Tapanainen, Pasi ^b   Manninen, Pekka ^b  

^a Apt F11   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL VALERATE PLUS NORGESTREL; LEVONORGESTREL; PHENACETIN O DEETHYLASE; TACRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033398110     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)90069-3     Document Type: Article

References (29)

1. 1. Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-30.
2. 2. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995;28:449-57.
3. 3. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327:1253-9.
4. 4. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166-77.
5. 5. Samuels SC, Davis KL. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Drug Saf 1997;16:66-77.
6. 6. Blackard WG Jr, Sood GK, Crowe DR, Fallon MB. Tacrine: a cause of fatal hepatotoxicity? J Clin Gastroenterol 1998;26:57-9.
7. 7. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJ. Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. Clin Pharmacol Ther 1989;46:634-41.
8. 8. Forgue ST, Reece PA, Sedman AJ, deVries TM. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996;59:444-9.
9. 9. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994;38:15-22.
10. 10. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23:929-34.
11. 11. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996;23:1429-35.
12. 12. Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, et al. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol 1998;46:221-8.
13. 13. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61:619-27.
14. 14. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
15. 15. van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 1998;30:27-36.
16. 16. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
17. 17. Rozenberg S, Vandromme J, Kroll M, Vasquez JB. Managing the climacteric. Int J Fertil Womens Med 1999;44:12-8.
18. 18. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
19. 19. Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. Am J Med 1997;103:46S-50S.
20. 20. Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990;3:363-71.
21. 21. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme ML. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol 1991;38: 219-25.
22. 22. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998;11:659-65.
23. 23. Eugster HP, Probst M, Wurgler FE, Sengstag C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2: evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos 1993; 21:43-9.
24. 24. Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug inter-action with female sex steroids. Br J Clin Pharmacol 1999;47:249-54.
25. 25. Haughey DB, McNaney CA, Collis MS, Brown RR, Siedlik PH, Balogh L, et al. Simultaneous determination of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxy-tacrine in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1994;83:1582-5.
26. 26. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18: 472-84.
27. 27. Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L, Sirtori CR. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin Pharmacol Ther 1991;49:278-84.
28. 28. Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995;48:161-6.
29. 29. Scavone JM, Greenblatt DJ, Abernethy DR, Luna BG, Harmatz JS, Shader RI. Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. J Clin Pharmacol 1997;37: 437-41.